SEC Form 4 · accession 0001140361-15-006591
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan W Ayers
Officer — Chairman, President & CEO · Director
Period of report
Feb 11, 2015
Accepted (ET)
Feb 13, 2015 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 11, 2015 | M | 29,000 | $56.95 | A | 460,130 | D | |
| Common StockF2 | Feb 11, 2015 | S | 10,218 | $154.0088 | D | 449,912 | D | |
| Common StockF3 | Feb 11, 2015 | S | 16,231 | $154.8267 | D | 433,681 | D | |
| Common StockF4 | Feb 11, 2015 | S | 2,551 | $155.7174 | D | 431,130 | D | |
| Common Stock | Feb 12, 2015 | M | 29,245 | $56.95 | A | 460,375 | D | |
| Common StockF5 | Feb 12, 2015 | S | 22,877 | $156.1584 | D | 437,498 | D | |
| Common StockF6 | Feb 12, 2015 | S | 5,768 | $156.5888 | D | 431,730 | D | |
| Common StockF7 | Feb 12, 2015 | S | 600 | $157.475 | D | 431,130 | D | |
| Common Stock | holding | — | — | — | 49,000 | I | By Ayers Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F8 | $56.95 | Feb 11, 2015 | M | 29,000 | D | — | Feb 13, 2015 | Common Stock | 29,000 | 29,245 | D |
| Non-Qualified Stock Option (right to buy)F8 | $56.95 | Feb 12, 2015 | M | 29,245 | D | — | Feb 13, 2015 | Common Stock | 29,245 | 0 | D |
Explanation of responses
- F1The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/28/2014.
- F2The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $153.32 to $154.31, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7, inclusive, to this Form 4.
- F3The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $154.32 to $155.31, inclusive.
- F4The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $155.38 to $155.83, inclusive.
- F5The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $155.46 to $156.45, inclusive.
- F6The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $156.46 to $156.84, inclusive.
- F7The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $157.46 to $157.49, inclusive.
- F8Grant of options to buy shares of common stock that became exercisable as to 12,000 shares on 02/14/2009, 02/14/2010, 02/14/2011 and 02/14/2012, and 10,245 shares on 02/14/2013.